Updates in treating NTRK fusion cancer: Highlights from ESMO 2019

Bookmark and Share
Published: 9 Mar 2020
Views: 1773
Prof Marc Peeters and Prof Jesus Garcia-Foncillas

ESMO 2019 was, as always, a prime opportunity to learn the latest data surrounding all areas of oncology. A number of abstracts and posters were also featured on NTRK fusion cancer. Together, our Chair Professor Marc Peeters and our guest speaker Professor Jesus Garcia-Foncillas selected 4 abstracts to discuss in this summary session. These are:

  • • 45PD - Durability of response with larotrectinib in adult and paediatric patients with TRK fusion cancer

  • • 485P - Growth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and paediatric tumours

  • • 443PD - Genomic characteristics and predicted ancestry of NTRK1/2/3 and ROS1 fusion-positive tumours from >165,000 pan-solid tumours

  • • 1488PD - Entrectinib in Locally Advanced/Metastatic ROS1 and NTRK Fusion-Positive Non-Small Cell Lung Cancer (NSCLC): Updated Integrated Analysis

This independent educational activity is supported by an educational grant from Bayer Pharmaceuticals. The educational content has been developed by Liberum IME and validated by an independent steering committee; Bayer Pharmaceuticals have had no influence on the content of this education.

To earn CME credits and discover further Publication to Practice sessions, please visit Oncology Knowledge into Practice.